CordenPharma has signed a multi-year agreement for the contract manufacture of a large-volume launch peptide at its former Roche facility in Boulder, Colorado. This will begin in 2023 and will potentially be worth about $1 billion, depending on actual production levels required. The customer has not been named and no further details are being disclosed.
In response to an increasing number of projects, notably in oncology, Indian CRDMO Sai Life Sciences, has opened a 1,485 m2 high potency API (HPAPI) facility at its cGMP API campus in Bidar. This follows on from the opening of an HPAPI development facility at the Hyderabad R&D campus.
The company said that this expands its expertise “across HPAPI development and manufacturing, providing its customers with a streamlined pathway for NCE development”. It will now be able to handle all aspects of the product life cycle.
UK-based CDMO Sterling Pharma Solutions has completed the acquisition of Novartis’ API facility in Ringaskiddy, near Cork, Ireland. The deal includes an on-going supply agreement to make APIs for cardiovascular, immunology and oncology medicines for Novartis. No financial details were disclosed.
Granules India and Greenko ZeroC have formed a strategic partnership to promote ‘integrated green pharmaceutical zones’. The first part will be a 40-hectare greenfield facility at Kakinada, Andhra Pradesh, for large-scale manufacturing of key starting materials, intermediates, APIs and fermentation-based products, including DCDA, PAP, paracetamol and metformin.
Canary Wharf Group and Kadans Science Partner have submitted a detailed planning application for a 23-storey, 76,500 m2 tower. They said that this would be Europe’s largest and most technologically advanced life sciences facility, as well as a first of its kind vertical campus.
The site is on an undeveloped 3.5-hectare site at the North Quay on Canary Wharf in the Docklands area of London. It will be able to deliver 325,000 m2 of laboratory and affiliated space, with the ability to provide chemistry and high containment facilities. Other features will include:
Bachem has signed a further work order with an unnamed customer for large volumes of peptides for a minimum total of CHF 1 billion from 2025 to 2029. This follows two previous large-volume contracts announced in September worth CHF 175 million in 2023-4. No further details will be disclosed.
Clariant is to invest CHF 80 million to expand its Care Chemicals facility at Daya Bay in Huizhou, China, by the end of 2024. This will both add capacity for existing products and introduce new products in the pharmaceutical, personal care, home care and industrial sector.
Daya Bay, which has obtained the drug GMP certificate, is the first API site in China certified to produce polyethylene glycol Polyglykol 3350. More generally, it will become new global hub for Clariant’s healthcare business support.
